Levi & Korsinsky Reminds Aardvark Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 13, 2026 - AARD
Pension funds, asset managers, and other fiduciaries holding Aardvark Therapeutics, Inc. (NASDAQ: AARD) positions acquired in or after the February 2025 IPO may wish to evaluate lead plaintiff options, as a securities class action alleges the Company misrepresented the safety and tolerability of ARD-101 before a Phase 3 trial pause and a full FDA clinical hold.
Levi & Korsinsky, LLP notifies institutional investors in Aardvark Therapeutics, Inc. (NASDAQ: AARD) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between February 13, 2025 and May 14, 2026. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.
Shares sold at the $16.00 IPO price now trade near $4.57, a decline of approximately $11.43 per share, or 71.4%. Aardvark issued 5,888,000 shares for proceeds of $87,613,440. To be considered for lead plaintiff, investors must file by October 13, 2026.
Notice to Institutional Holders
